Needham reiterates Buy on Lucid Diagnostics following investor day By Investing.com – Canada Boosts
© Reuters. Needham reiterates Purchase on Lucid Diagnostics (LCUD) following investor day Needham reiterated a Purchase score, and 12-month worth goal of $2.50, on Lucid Diagnostics (LUCD) after attending the corporate’s investor day occasion on Tuesday. Needham attended Lucid’s investor day assembly on New York Tuesday the place the medical firm outlined their working mannequin…
